As of July 24, 2012 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information .
1. E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy vs. High Dose Interferon a-2b for Resected High Risk Melanoma
The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better. In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b.
High doses of interferon alfa-2b can reduce the risk of melanoma returning, but only some patients benefit from interferon. This interferon is commercially available. We hope to find a more effective and long-lasting treatment for your type of cancer. Ipilimumab is a biological agent that has been shown to have anti-tumor activity in advanced melanoma. Interferon alfa-2b is FDA-approved as an adjuvant treatment to surgery in adult patients with melanoma who are free of disease but at high risk for recurrence. Ipilimumab is investigational and has not been approved by the FDA for use in this cancer.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133